Beta
ManageChatDiscover
415889

Silymarin for the Prevention of Contrast-Induced Nephropathy after Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction

Article

Last updated: 09 Mar 2025

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Background: Contrast-induced nephropathy (CIN) is a serious complication of angiographic procedures, increasing morbidity and mortality. Oxidative stress and inflammation play key roles in its pathogenesis. Silymarin, a flavonoid complex with antioxidant and anti-inflammatory properties, may offer renal protection. Objective: To assess the protective effect of a single dose of silymarin against CIN in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Patients and Methods: In this prospective interventional study, 200 STEMI patients undergoing PPCI were randomized into two equal groups. The study group received 140 mg of silymarin alongside standard dual antiplatelet therapy, while the control group received standard therapy alone. Renal function was assessed at baseline and post-procedure using serum creatinine and estimated glomerular filtration rate (eGFR). CIN was defined as a ≥25% increase in serum creatinine or an absolute rise of ≥0.5 mg/dL within 48–72 hours post-contrast exposure. Results: CIN incidence was significantly lower in the silymarin group (12.0% vs. 28.0%, p = 0.005). Post-procedural serum creatinine increase was smaller (ΔS. Creat: 0.18 ± 0.28 vs. 0.35 ± 0.42 mg/dL, p = 0.011), with a lesser eGFR reduction (ΔGFR: -8.63 ± 17.43 vs. -18.21 ± 23.95 mL/min, p < 0.001). Contrast volume and procedural duration were higher in the study group (p < 0.001, p = 0.003). Conclusion: A single dose of silymarin significantly reduced CIN incidence in STEMI patients undergoing PPCI, highlighting its potential nephroprotective effect in high-risk populations.  

DOI

10.21608/ejhm.2025.415889

Keywords

Silymarin, contrast-induced nephropathy, ST-elevation myocardial infarction, percutaneous coronary intervention, nephroprotection

Volume

98

Article Issue

1

Related Issue

52551

Issue Date

2025-01-01

Receive Date

2025-03-05

Publish Date

2025-01-01

Page Start

971

Page End

976

Print ISSN

1687-2002

Online ISSN

2090-7125

Article File

EJHM_Volume 98_Issue 1_Pages 971-976.pdf

PDF . 377.2kB

Link

https://ejhm.journals.ekb.eg/article_415889.html

Detail API

http://journals.ekb.eg?_action=service&article_code=415889

Order

142

Type

Original Article

Type Code

606

Publication Type

Journal

Publication Title

The Egyptian Journal of Hospital Medicine

Publication Link

https://ejhm.journals.ekb.eg/

MainTitle

Silymarin for the Prevention of Contrast-Induced Nephropathy after Percutaneous Coronary Intervention in Patients with Acute ST-Segment Elevation Myocardial Infarction

Details

Type

Article

Created At

09 Mar 2025